pyrroles has been researched along with Angiosarcoma in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, R; Aoyagi, S; Fujita, Y; Hata, H; Hoshina, D; Saito, N; Shimizu, H; Yoshioka, N | 1 |
| Choorapoikayil, S; de Bruin, A; den Hertog, J; Kers, R; Weijts, B | 1 |
| Kaneda, Y; Katayama, I; Masuzawa, M; Nakamura, M; Nishizawa, A; Saeki, K; Satoh, T; Takehara, Y; Yokozeki, H | 1 |
| Bergman, P; Clifford, C; Crawford-Jakubiak, M; Gardner, HL; Garrett, LD; Henry, C; Klein, MK; Locke, J; London, CA; Nguyen, S; Portela, RA; Rosenberg, MP; Thamm, DH; Vail, DM | 1 |
| Debiec-Rychter, M; Lambrechts, D; Mazzone, M; Prenen, H; Sagaert, X; Sciot, R; Smeets, D | 1 |
| Buehler, D; Cleary, K; Hafez, GR; Hasenstein, JR; Kasmerchak, K; Kozak, KR; Moody, JS | 1 |
| Chao, TC; Chen, PC; Hsiao, FC; Lu, HJ; Ma, H; Shiau, CY; Tzeng, CH; Yen, CC | 1 |
| Aimone, LD; Albom, M; Angeles, TS; Ator, MA; Dionne, CA; Gingrich, DE; Hudkins, RL; Iqbal, MA; Mallamo, JP; Meyer, SL; Reddy, DR; Robinson, C; Ruggeri, BA; Singh, J; Vaught, JL; Yang, S | 1 |
8 other study(ies) available for pyrroles and Angiosarcoma
| Article | Year |
|---|---|
Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Hemangiosarcoma; Heterografts; Humans; In Vitro Techniques; Indoles; Male; Mice; Mice, Inbred NOD; Mice, SCID; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction; Skin Neoplasms; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
Loss of Pten promotes angiogenesis and enhanced vegfaa expression in zebrafish.
Topics: Animals; Chromones; Drug Therapy, Combination; Endothelial Cells; Haploinsufficiency; Hemangiosarcoma; Humans; Indoles; Morpholines; Mutation; Neovascularization, Pathologic; Phosphoprotein Phosphatases; Proto-Oncogene Proteins c-akt; Pseudopodia; Pyrroles; RNA, Messenger; Sunitinib; Up-Regulation; Vascular Endothelial Growth Factor A; Zebrafish; Zebrafish Proteins | 2013 |
Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Dendritic Cells; Female; Hemangiosarcoma; Indoles; Interferon-gamma; Interleukin-2; Lymphocytes; Mice; Mice, Inbred BALB C; Oncolytic Virotherapy; Protein Kinase Inhibitors; Pyrroles; Sendai virus; Skin Neoplasms; Sunitinib; Tumor Burden; Virion | 2013 |
Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Doxorubicin; Female; Hemangiosarcoma; Indoles; Male; Pyrroles; Splenic Neoplasms | 2015 |
Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma.
Topics: Antineoplastic Agents; Cytogenetics; Female; Hemangiosarcoma; Humans; Indoles; Liver Neoplasms; Middle Aged; Mutation; Phospholipase C gamma; Pyrroles; Signal Transduction; Sunitinib | 2015 |
Efficacy of Tie2 receptor antagonism in angiosarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Hemangiosarcoma; Humans; Imidazoles; Indoles; Mice; Mice, Nude; Pyridines; Pyrroles; Receptor, TIE-2; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Xenograft Model Antitumor Assays | 2012 |
Refractory cutaneous angiosarcoma successfully treated with sunitinib.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Female; Hemangiosarcoma; Humans; Indoles; Pyrroles; Skin Neoplasms; Sunitinib; Treatment Outcome | 2013 |
A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-521
Topics: Angiogenesis Inhibitors; Animals; Carbazoles; Cells, Cultured; Drug Screening Assays, Antitumor; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Female; Hemangiosarcoma; Humans; In Vitro Techniques; Indenes; Liver; Male; Mice; Mice, Nude; Models, Molecular; Phosphorylation; Prodrugs; Pyrroles; Rats; Rats, Sprague-Dawley; Sarcosine; Solubility; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2003 |